Skip to content

Oasmia Pharmaceutical AB

CIK 0001607245

← back to feed
Revenue (TTM)
3.17M
+1,742.4% YoY FY Jul 2018
Net Income (TTM)
−118.01M
+26.4% YoY FY Jul 2018
EPS Diluted (TTM)
—
FY Jul 2018
Gross Margin
—
FY Jul 2018
Operating Margin
-3,273.1%
FY Jul 2018
Net Margin
-3,724.0%
FY Jul 2018
Free Cash Flow (TTM)
—
FY Jul 2018
Cash
15.58M
FY Jul 2018
Total Debt
—
FY Jul 2018
Shares Outstanding
179.31M sh
FY Jul 2018

Revenue & Net Income

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings